Of the receptors, FGFR4 is considered a potent target of lenvatinib in the treatment of HCC (44), providing a mechanistic rationale for that lenvatinib resulted in a statistically significant improvement in ORR compared with sorafenib in REFLECT trial. Here, FGFR4 is linked to hepatocellular carcinoma.